Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)

Kura Oncology has reported Current Deferred Revenue over the past 3 years, most recently at $47.7 million for Q1 2026.

  • Quarterly Current Deferred Revenue rose 16.79% to $47.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.7 million through Mar 2026, up 16.79% year-over-year, with the annual reading at $49.0 million for FY2025, 101.82% up from the prior year.
  • Current Deferred Revenue was $47.7 million for Q1 2026 at Kura Oncology, down from $49.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $49.4 million in Q2 2025 and troughed at $24.3 million in Q4 2024.
  • The 3-year median for Current Deferred Revenue is $48.2 million (2025), against an average of $43.3 million.
  • Year-over-year, Current Deferred Revenue surged 101.82% in 2025 and then rose 16.79% in 2026.
  • A 3-year view of Current Deferred Revenue shows it stood at $24.3 million in 2024, then skyrocketed by 101.82% to $49.0 million in 2025, then decreased by 2.61% to $47.7 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Current Deferred Revenue are $47.7 million (Q1 2026), $49.0 million (Q4 2025), and $48.8 million (Q3 2025).